According to the disclosure of the HKEx on April 29th, Shanghai Inuowei Medical Devices Co., Ltd. submitted the form to the main board of the HKEx, with Goldman Sachs Group and China International Capital Corporation as co-sponsors.

It is reported that Invid is China's leading provider of integrated solutions for non-vascular interventional surgery with a global vision. According to CIC, since its establishment in 2009, the company has established a leading proprietary technology platform and formed economies of scale. It has become one of the few companies in the world that can provide endoscopes, active medical devices and passive consumables integration solutions for all major medical specialties for non-vascular interventional surgery in urology, gastroenterology, hepatobiliary surgery, respiratory, thoracic surgery, otorhinolaryngology, gynecology and general surgery.

On the financial front, the company's revenue increased by 85.9% from 137.3 million yuan in 2020 to about 255 million yuan in 2021. In China, the company's revenue rose 103.5 per cent from 89.1 million yuan in 2020 to about 181 million yuan in 2021. The company's revenue from endoscope sales was 51.4 million yuan in 2020, an increase of 113.6 percent to about 110 million yuan in 2021.